Search

Search Constraints

You searched for: Author/Creator Feldmann, Marc

Search Results

2. Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial. (June 2022)